Phase III Study of 5LGr to Treat Tic Disorder

• Status: Completed
• Trial end date: 2011-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the effective and safety of 5LGr in pediatric patients with tic disorders.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tasly Pharmaceuticals, Inc.
• Treatments: Tiapride Hydrochloride

Criteria

Inclusion Criteria:

• >1 year history of diagnosed tic disorder;

• age:5-18 yrs;

• YGTSS score>=30 at baseline.

Exclusion Criteria:

• Diagnosed with hyperactivity disorder,epilepsy,chorea,autism,obsessive-compulsive disorder,mental retardation,athetosis,Wilson's disease.

• Any indefinite tic disorder or tic disorders caused by medication.

• Participation to other studies.

• Patients with loose stool.